Abstract
Serum and dialysate levels of amikacin were determined at appropriate intervals after a 300-mg intravenous dose as a continuous infusion in six patients with end-stage renal failure undergoing hemodialysis and in three patients on peritoneal dialysis. The mean serum half-life of amikacin was 3.75 h during (or after) hemodialysis and 29 h during (or after) peritoneal dialysis. Although not on hemodialysis in the same six patients, the serum half-life was 28 h. The results indicate that the maintenance dose of amikacin should be markedly decreased in patients with severe renal failure even if they are treated with peritoneal dialysis, and that serial serum antibiotic concentrations are essential to prevent cumulative toxicity of the drug.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bodey G. P., Valdivieso M., Feld R., Rodriguez V. Pharmacology of amikacin in humans. Antimicrob Agents Chemother. 1974 May;5(5):508–512. doi: 10.1128/aac.5.5.508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kawaguchi H., Naito T., Nakagawa S., Fujisawa K. I. BB-K 8, a new semisynthetic aminoglycoside antibiotic. J Antibiot (Tokyo) 1972 Dec;25(12):695–708. doi: 10.7164/antibiotics.25.695. [DOI] [PubMed] [Google Scholar]
- Price K. E., Chisholm D. R., Misiek M., Leitner F., Tsai Y. H. Microbiological evaluation of BB-K 8, a new semisynthetic aminoglycoside. J Antibiot (Tokyo) 1972 Dec;25(12):709–731. doi: 10.7164/antibiotics.25.709. [DOI] [PubMed] [Google Scholar]